» Articles » PMID: 15494909

The Effect of Initial Drug Resistance on Treatment Response and Acquired Drug Resistance During Standardized Short-course Chemotherapy for Tuberculosis

Overview
Journal Clin Infect Dis
Date 2004 Oct 21
PMID 15494909
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In Tomsk Oblast, Russian Federation, during the period of 1996-2000, most previously untreated patients with tuberculosis received standardized short-course chemotherapy, irrespective of drug-susceptibility testing results. A retrospective analysis was done to determine the effect of initial drug resistance on treatment outcome and acquired drug resistance in new patients receiving standardized short-course chemotherapy.

Methods: During the period of 1 November 1996 through 31 December 2000, a total of 2194 patients received a category 1 treatment regimen. Drug susceptibility test results for 1681 patients were available for analysis. Drug resistance patterns before and during treatment were compared for 73 patients whose culture results were persistently positive during treatment. Acquired resistance was defined as new drug resistance (during or at the end of treatment) that was not present at the beginning of treatment.

Results: Pretreatment drug resistance was strongly associated with treatment failure. In patients who had strains with pretreatment resistance patterns that included isoniazid or rifampin resistance, but not resistance to both, 17 (70.8%) of 24 cases involving treatment failures acquired new multidrug resistance. In patients with pretreatment pan-susceptible or streptomycin-monoresistant strains, 13 (41.9%) of 31 cases involving treatment failures acquired new multidrug resistance.

Conclusions: Early diagnosis of drug-resistant tuberculosis and judicious use of second-line drugs is recommended to decrease transmission of drug-resistant strains and to prevent the creation of multidrug-resistant strains. Finally, if drug susceptibility tests are not available or results are delayed, physicians should recognize that patients who do not respond to directly observed empirical short-course chemotherapy are at high risk of having multidrug-resistant tuberculosis and should be treated accordingly.

Citing Articles

Recent Biochemical Advances in Antitubercular Drugs: Challenges and Future.

Jain A, Kumar R, Mothsra P, Sharma A, Singh A, Kumar Y Curr Top Med Chem. 2024; 24(21):1829-1855.

PMID: 38919089 DOI: 10.2174/0115680266286294240610102911.


Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis.

Menzies N, Allwood B, Dean A, Dodd P, Houben R, James L Nat Commun. 2023; 14(1):6182.

PMID: 37794037 PMC: 10550952. DOI: 10.1038/s41467-023-41937-9.


Evaluation of treatment regimens and long-term clinical outcomes in patients with isoniazid-resistant pulmonary tuberculosis: a 5-year follow-up.

Aslan A, Ortakoylu M, Bagci B, Toprak S Turk J Med Sci. 2023; 53(3):761-770.

PMID: 37476899 PMC: 10388119. DOI: 10.55730/1300-0144.5639.


Tuberculosis: National survey in India & elimination challenges reflected through global learning.

Panda S Indian J Med Res. 2023; 157(2&3):111-113.

PMID: 37006027 PMC: 10319388. DOI: 10.4103/ijmr.ijmr_541_23.


Mycobacterium Time-Series Genome Analysis Identifies AAC2' as a Potential Drug Target with Naloxone Showing Potential Bait Drug Synergism.

Niranjan V, Uttarkar A, Murali K, Niranjan S, Gopal J, Kumar J Molecules. 2022; 27(19).

PMID: 36234683 PMC: 9571707. DOI: 10.3390/molecules27196150.